Ocular Side Effects of EGFR-Inhibitor ABT-414 in Recurrent Glioblastoma: A Long-Term Safety Study.

ABT-414 confocal microscopy cornea epidermal growth factor receptor-inhibitor glioblastoma long-term follow-up side effects sub-basal nerve plexus

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2020
Historique:
received: 10 08 2020
accepted: 28 09 2020
entrez: 6 11 2020
pubmed: 7 11 2020
medline: 7 11 2020
Statut: epublish

Résumé

This study aimed to prospectively evaluate, on a long-term basis, corneal side effects secondary to compassionate administration of epidermal growth factor receptor (EGFR) inhibitor depatuxizumab mafodotin (ABT-414) in patients affected by EGFR-amplified recurrent glioblastoma. Fifteen patients with a median follow-up of 4.3 months after treatment discontinuation were enrolled. Each patient underwent full ophthalmologic examination including

Identifiants

pubmed: 33154952
doi: 10.3389/fonc.2020.593461
pmc: PMC7591744
doi:

Types de publication

Journal Article

Langues

eng

Pagination

593461

Informations de copyright

Copyright © 2020 Parrozzani, Lombardi, Midena, Londei, Padovan, Marchione, Caccese, Midena, Zagonel and Frizziero.

Références

Cancers (Basel). 2019 Nov 20;11(12):
pubmed: 31756933
Neuro Oncol. 2020 May 15;22(5):684-693
pubmed: 31747009
Ther Adv Med Oncol. 2020 May 27;12:1758835920907543
pubmed: 32550861
CA Cancer J Clin. 2020 Jul;70(4):299-312
pubmed: 32478924
Case Rep Ophthalmol. 2018 Nov 29;9(3):479-483
pubmed: 30631275
Surv Ophthalmol. 2001 Mar;45 Suppl 2:S221-6
pubmed: 11587146
Neuro Oncol. 2019 Jan 1;21(1):106-114
pubmed: 29982805
Neurotherapeutics. 2017 Apr;14(2):307-320
pubmed: 28108885
Eye (Lond). 2005 Jul;19(7):729-38
pubmed: 15688060
Mol Cancer Ther. 2015 May;14(5):1141-51
pubmed: 25731184
Mol Cancer Ther. 2016 Apr;15(4):661-9
pubmed: 26846818
Transl Oncol. 2020 Sep;13(9):100795
pubmed: 32470910
Neuro Oncol. 2018 May 18;20(6):838-847
pubmed: 29077941
J Exp Ther Oncol. 2019 Dec;13(2):81-118
pubmed: 31881126
Cancer. 2018 May 15;124(10):2174-2183
pubmed: 29533458
Exp Eye Res. 2001 May;72(5):511-7
pubmed: 11311043
Korean J Ophthalmol. 2011 Oct;25(5):355-7
pubmed: 21976946
J Ocul Pharmacol Ther. 2015 Dec;31(10):589-604
pubmed: 26539624
Neuro Oncol. 2017 Jul 1;19(7):965-975
pubmed: 28039367

Auteurs

Raffaele Parrozzani (R)

Department of Ophthalmology, University of Padova, Padova, Italy.

Giuseppe Lombardi (G)

Department of Oncology, Oncology 1, Veneto Institute of Oncology-IRCCS, Padua, Italy.

Edoardo Midena (E)

Department of Ophthalmology, University of Padova, Padova, Italy.
IRCCS-Fondazione Bietti, Rome, Italy.

Davide Londei (D)

Department of Ophthalmology, University of Padova, Padova, Italy.

Marta Padovan (M)

Department of Oncology, Oncology 1, Veneto Institute of Oncology-IRCCS, Padua, Italy.

Giulia Marchione (G)

Department of Ophthalmology, University of Padova, Padova, Italy.

Mario Caccese (M)

Department of Oncology, Oncology 1, Veneto Institute of Oncology-IRCCS, Padua, Italy.

Giulia Midena (G)

Unità Operativa Complessa Oftalmologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Vittorina Zagonel (V)

Department of Oncology, Oncology 1, Veneto Institute of Oncology-IRCCS, Padua, Italy.

Luisa Frizziero (L)

IRCCS-Fondazione Bietti, Rome, Italy.

Classifications MeSH